Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options
NCT ID: NCT03583164
Last Updated: 2024-07-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
203 participants
INTERVENTIONAL
2018-06-06
2023-02-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Olorofim Aspergillus Infection Study
NCT05101187
F901318 Single Ascending Dose Study in Healthy Male Volunteers
NCT02142153
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
NCT03340597
Anidulafungin in Patients With Hematologic Malignancies
NCT01053884
F901318 Multiple Ascending Dose Study
NCT02342574
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Olorofim (F901318)
Olorofim (F901318) was given orally for up to 90 days in the Main Study Phase and could be continued for those participants entering the Extended Treatment Phase.
Patients received fixed doses comprising of a 1-day loading dose of 150 mg of olorofim twice a day followed by a maintenance dose of 90 mg of olorofim twice a day.
Up until Protocol Amendment 06, 58 patients received a weight-based olorofim dosing consisting of a 1-day loading dose of 4 mg/kg/day on Day 1, then a maintenance dose of 2.5 mg/kg/day (divided into 2 or 3 doses). The dose was then adjusted based on plasma levels of olorofim with the maximum total daily dose of 300 mg.
Olorofim
30mg oral tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olorofim
30mg oral tablets
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability and willingness to comply with the protocol.
* Able to take oral medication
* Females must be non-lactating and at no risk of pregnancy
* Male with female partners of childbearing potential must either abstain from sexual intercourse or use a highly effective means of contraception
* Participants with invasive fungal disease
* Participants who have limited alternative treatment options
Exclusion Criteria
* Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug.
* Participants with chronic aspergillosis, aspergilloma or allergic bronchopulmonary aspergillosis.
* Human Immunodeficiency Virus (HIV) infection but not currently receiving antiretroviral therapy.
* Participants with a medical condition that may jeopardize adherence to the protocol or may cause unacceptable additional risk to the participant
* Previously enrolled participants or participants enrolled in any clinical trial within the last 30 days
* Participants receiving treatment limited to supportive care due to predicted short survival time.
* Prohibited concomitant medications.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Iqvia Pty Ltd
INDUSTRY
F2G Biotech GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon Chen
Role: PRINCIPAL_INVESTIGATOR
Westmead Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Valley Fever Institute at Kern Medical Center
Bakersfield, California, United States
UC Davis Medical Center
Sacramento, California, United States
University of California San Diego Medical Center
San Diego, California, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Weill Cornell Medical College
New York, New York, United States
Stony Brook University Medical Center
Stony Brook, New York, United States
Duke University Health System
Durham, North Carolina, United States
UPMC
Pittsburgh, Pennsylvania, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Peter MacCallum Centre-East Melbourne
Melbourne, Victoria, Australia
Royal Melbourne Hospital
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
UZ Leuven
Leuven, Waals-Brabant, Belgium
Institut Jules Bordet
Brussels, , Belgium
Hôpital Erasme
Brussels, , Belgium
Hospital Felício Rocho
Belo Horizonte, Minas Gerais, Brazil
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
HC - UFPR - Hospital de Clínicas da Universidade Federal do Paraná
Curitiba, Paraná, Brazil
Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital da Universidade Federal de Santa Maria CEP/UFSM
Santa Maria, Rio Grande do Sul, Brazil
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
Curitiba, , Brazil
Santa Casa de Misericórdia de Passos
Passos, , Brazil
Oncology Center, Mansoura University
Al Mansurah, , Egypt
Alexandria University Hospital
Alexandria, , Egypt
Cairo University Hospitals
Cairo, , Egypt
Ain Shams University Hospital
Cairo, , Egypt
Air Force Specialized Hospital
Cairo, , Egypt
National Cancer Institute
Cairo, , Egypt
Nasser Institute
Cairo, , Egypt
CHU Strasbourg - Hôpital Hautepierre
Strasbourg, Bas Rhin, France
CHU de Grenoble - Hôpital Albert Michallon
Grenoble, Isere, France
Hôpital Necker - Enfants Malades
Paris, Paris, France
Hôpital Saint-Louis
Paris, , France
Klinikum der Universitaet Muenchen Campus Grosshadern
Munich, Bavaria, Germany
Universitaetsklinikum Koeln
Cologne, North Rhine-Westphalia, Germany
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, , Germany
Charite-Campus Benjamin Franklin (CBF)
Berlin, , Germany
Soroka University Medical Center
Beersheba, , Israel
Rambam Health Care Campus
Haifa, , Israel
Hadassah University Hospital - Ein Kerem
Jerusalem, , Israel
Chaim Sheba Medical Center
Ramat Gan, , Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, , Israel
Radboudumc
Nijmegen, , Netherlands
Erasmus Medisch Centrum
Rotterdam, , Netherlands
UMC Utrecht
Utrecht, , Netherlands
Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
SPZOZ Szpital Uniwersytecki w Krakowie
Krakow, , Poland
Wojewodzki Szpital Specjalistyczny im. J. Korczaka
Słupsk, , Poland
Instytut Hematologii i Transfuzjologii
Warsaw, , Poland
Leningrad Regional Clinical Hospital
Saint Petersburg, , Russia
FBI "Scientific Research Institute of Oncology n. a. N. N. Petrov"
Saint Petersburg, , Russia
Pavlov First Saint Petersburg State Medical University
Saint Petersburg, , Russia
SBEIHPE "NWSMU n. a. I.I Mechnikov" of MoH and SD of RH
Saint Petersburg, , Russia
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, , South Korea
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario Ramon y Cajal
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitari i Politecnic La Fe
Valencia, , Spain
Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
King Chulalongkorn Memorial Hospital
Pathum Wan, Bangkok, Thailand
Dicle University, Medical Faculty
Diyarbakır, , Turkey (Türkiye)
Acibadem Atakent Hospital
Istanbul, , Turkey (Türkiye)
Marmara University Pendik Research and Training Hospital
Istanbul, , Turkey (Türkiye)
King's College Hospital
London, Greater London, United Kingdom
Manchester Royal Infirmary
Manchester, Greater Manchester, United Kingdom
Wythenshawe Hospital
Manchester, Wythenshawe, United Kingdom
Bach Mai Hospital
Hanoi, , Vietnam
National Lung Hospital
Hanoi, , Vietnam
HCMC Hospital for Tropical Diseases
Ho Chi Minh City, , Vietnam
Blood Transfusion Hematology Hospital
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortun J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Sole A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Bruggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Lancet Infect Dis. 2025 Jun 17:S1473-3099(25)00224-5. doi: 10.1016/S1473-3099(25)00224-5. Online ahead of print.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F901318/0032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.